Anti-FGF-20 Antibody, clone 3I3-L2 ZooMAb® Rabbit Monoclonal

Description

• General description: We are committed to bringing you greener alternative products, which adhere to one or more of The 12 Principles of Green Chemistry.This antibody is Preservative-free, produced without the harm or sacrifice of animals and exceptionally stable to allow for ambient shipping and storage if needed and thus aligns with "Waste Prevention", "Designing Safer Chemicals" and "Design for Energy Efficiency". Click here for more information.
• Specificity: Clone 3I3-L2 is a ZooMAb® rabbit recombinant monoclonal antibody that specifically detects FGF-20. It targets an epitope within 24 amino acids from the N-terminal half.
• Immunogen: KLH-conjugated linear peptide corresponding to 24 amino acids from the N-terminal half of human FGF-20.
• Application: Quality Control TestingEvaluated by Western Blotting in Human cerebral cortex membrane preparations.Western Blotting Analysis: A 1:10,000 dilution of this antibody detected FGF-20 in Human cerebral cortex membrane preparations.Quality Control TestingEvaluated by Western Blotting in Human cerebral cortex membrane preparations.Western Blotting Analysis: A 1:10,000 dilution of this antibody detected FGF-20 in Human cerebral cortex membrane preparations.Tested ApplicationsImmunohistochemistry (Paraffin) Analysis: A 1:100 dilution from a representative lot detected FGF-20 in Human cerebral cortex tissue sections.Affinity Binding Assay: A representative lot of this antibody bound FGF-20 peptide with a KD of 1.0 x 10-12 in an affinity binding assay.Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user.
• Target description: Fibroblast growth factor 20 (UniProt: Q9NP95; also known as FGF-20) is encoded by the FGF20 gene (Gene ID: 26281) in human. FGF-20 is a homodimeric protein that serves as a neurotrophic factor and regulates the development and function of central nervous system. It is predominantly expressed in the cerebellum and substantia nigra. Human and rat FGF-20 display high degree of homology (~ 95%). It acts on proximal cells and significantly enhances the survival of dopaminergic neurons by activating the MAPK pathway through FGF receptor 1c. In the rat model of Parkinson′s disease, FGF-20 is shown to protect against the loss of dopaminergic neurons. It is shown to ACT® synergistically with FGF-2 to increase the number of dopaminergic neurons in primate embryonic stem cell–derived neurospheres composed of neural progenitors. Exposure to FGF-20, along with Wnt5a and FGF-2, during the final stage of in vitro differentiation, can enhance the maturation and in vivo survival of dopaminergic neurons. Mutations in FGF20 gene have been linked to Renal hypodysplasia/aplasia 2 (RHDA2), a perinatally lethal renal disease with kidney development defects, bilateral renal aplasia, hypoplasia, and severe obstructive uropathy. This ZooMAb® recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, Affinity™, reproducibility, and stability over conventional monoclonals. (Ref.: Itoh, N., and Ohta, H. (2013). Front. Mol. Neurosci. 6; 15; Ohmachi, S., et al. (2000). Biochem. Biophys. Res. Commun. 277(2); 355-360).
• Physical form: Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS, 5% Trehalose, normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 µL.
• Reconstitution: 300 µg/mL after reconstitution at 25 µL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.
• Storage and Stability: Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 µL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.
• Other Notes: Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
• Legal Information: ACT is a registered trademark of Merck KGaA, Darmstadt, Germany
• Disclaimer: Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.